Security
Abivax SA Ordinary Shares (France) · AAVXF
AAVXFOTCCommon stockCurrentCIK 1956827Updated Nov 17, 2026
AAVXF price & chart
Loading TradingView…
OTC:AAVXF on TradingView ↗About the company
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
In the news
No coverage from other publishers is available.
Financials
FY 2025 · EURSource
Source
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossEUR | — | — | -153,358,000Source | -55,227,000Source | -48,414,000Source | -38,771,000Source | -52,370,000Source | -42,867,000Source | -336,102,000Source | -176,242,000Source | -147,740,000Source | -60,740,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForIncomeTaxExpenseEUR | — | — | — | — | — | — | — | — | 5,848,000Source | — | — | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableEUR | — | — | — | — | — | — | 12,754,000Source | 5,199,000Source | -6,210,000Source | -3,444,000Source | 31,757,000Source | -2,388,000Source |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | — | 4,689,000Source | 5,755,000Source | 35,397,000Source | 20,224,000Source | 8,179,000Source | -1,164,000Source |
| GeneralAndAdministrativeExpenseEUR | — | — | 25,500,000Source | 7,375,000Source | 8,270,000Source | 9,796,000Source | 8,033,000Source | 8,136,000Source | 67,670,000Source | 32,946,000Source | 22,390,000Source | 7,492,000Source |
| GoodwillEUR | — | — | 18,419,000Source | — | 18,419,000Source | — | 18,419,000Source | — | 18,419,000Source | 18,419,000Source | 18,419,000Source | 18,419,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| IncreaseDecreaseInWorkingCapitalEUR | — | — | — | — | — | — | -9,011,000Source | -3,921,000Source | -3,651,000Source | -1,423,000Source | -21,265,000Source | 2,002,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 1,965,000Source | 1,070,000Source | 6,490,000Source | 7,696,000Source | 5,279,000Source | 4,015,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 230,000Source | 143,000Source | 911,000Source | 458,000Source | 529,000Source | 301,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | 175,000,000Source | — | 125,000,000Source | — |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | — | — | — | 648,124,000Source | 0Source | 353,377,000Source | 46,231,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | — | 0Source | 3,000Source | 0Source | 35,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.25Source | 0.25Source | — | — |
| BasicEarningsLossPerShareEUR/shares | — | — | -2.1Source | -0.87Source | -0.76Source | -0.62Source | -0.83Source | -0.68Source | -4.83Source | -2.8Source | -3.43Source | -3.18Source |
| DilutedEarningsLossPerShareEUR/shares | — | — | -2.1Source | -0.87Source | -0.76Source | -0.62Source | -0.83Source | -0.68Source | -4.83Source | -2.8Source | -3.43Source | -3.18Source |
| FinanceCostsEUR | — | — | 93,051,000Source | 8,474,000Source | 5,415,000Source | 7,056,000Source | 6,723,000Source | 4,228,000Source | 111,743,000Source | 16,991,000Source | 27,875,000Source | 7,022,000Source |
| FinanceIncomeEUR | — | — | 20,404,000Source | 3,436,000Source | 3,497,000Source | 3,612,000Source | 1,552,000Source | 6,031,000Source | 27,545,000Source | 13,732,000Source | 7,511,000Source | 11,118,000Source |
| GeneralAndAdministrativeExpenseEUR | — | — | 25,500,000Source | 7,375,000Source | 8,270,000Source | 9,796,000Source | 8,033,000Source | 8,136,000Source | 67,670,000Source | 32,946,000Source | 22,390,000Source | 7,492,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 5,848,000Source | 0Source | 0Source | 0Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | 15,000Source | 18,000Source | 17,000Source | 20,000Source | 19,000Source | 5,000Source | 64,000Source | 61,000Source | 13,000Source | 10,000Source |
| OtherFinanceCostEUR | — | — | 8,000Source | 15,000Source | — | — | 6,000Source | 5,000Source | 29,000Source | 64,000Source | 73,000Source | 83,000Source |
| OtherIncomeEUR | — | — | 2,043,000Source | 1,324,000Source | 1,093,000Source | 5,628,000Source | 994,000Source | 1,186,000Source | 4,570,000Source | 12,449,000Source | 4,621,000Source | 4,583,000Source |
| ProfitLossBeforeTaxEUR | — | — | -153,358,000Source | -55,227,000Source | -48,414,000Source | -38,770,000Source | -52,370,000Source | -42,867,000Source | -330,254,000Source | -176,242,000Source | -147,740,000Source | -60,740,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | — | -80,712,000Source | -50,189,000Source | -46,496,000Source | -35,326,000Source | -47,200,000Source | -44,671,000Source | -246,056,000Source | -172,984,000Source | -127,376,000Source | -64,836,000Source |
| ResearchAndDevelopmentExpenseEUR | — | — | 55,416,000Source | 43,286,000Source | 38,645,000Source | 28,907,000Source | 39,301,000Source | 35,744,000Source | 177,761,000Source | 146,532,000Source | 103,176,000Source | 48,295,000Source |
| RevenueFromInterestEUR | — | — | 3,361,000Source | 1,983,000Source | 190,000Source | 2,277,000Source | 859,000Source | 2,534,000Source | 5,600,000Source | 8,246,000Source | 2,418,000Source | 0Source |
Filing attachments
d86113dex44.htm · POSASR · 2026-06-30
Exhibit 4.4 ABIVAX SA, as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of ______, 20__ Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d110874dex991.htm · 6-K · 2026-06-29
Exhibit 99.1 Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis (“UC”) population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treat…
Read attachment ↗d98688dex991.htm · 6-K · 2026-06-02
Exhibit 99.1 Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001) Both 25 mg and 50 mg obefazimod met all key secondary endpoints, demonstrating robust and clinica…
Read attachment ↗d148287dex991.htm · 6-K · 2026-05-07
Exhibit 99.1 Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Cash runway remains into Q4 2027, supporting continued funding of clinical programs and pre-commercial planning activities ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Royalty overhang materially reduced, enhancing financial flexibility to support future commercialization …
Read attachment ↗